Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 33Melanosis 3Carcinoma, Basal Cell 2Warts 1Keratosis, Seborrheic 1Keratosis 1Condylomata Acuminata 1Carcinoma, Squamous Cell 1Bowen's Disease 1

Interventions

resiquimod 6VP-102 2N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2Cantharidin 22-Propanol 2methyl 5-aminolevulinate 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1Sugars 1Photochemotherapy 1Nitric Oxide 1Maltose 1Interferon-alpha 1Imiquimod 1Exercise 1Equipment and Supplies 1Cryotherapy 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Warts × 3-ingenyl angelate × Clear all
NCT00546611 2016-01-28

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Peplin

Phase 1 Withdrawn

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡